Johnson & Johnson drops SHPI (Specialised Health Products International) and its safety needle technology
This article was originally published in Clinica
Johnson & Johnson subsidiary Ethicon Endo-Surgery has discontinued a development and licensing deal with safety needle product company Specialised Health Products International (SHPI). The company had expected a product launch would take place this month. SHPI now says that, as a result of its "precarious financial position", it is now evaluating its ability to continue as a going concern.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.